This study is looking at how a special imaging agent, called [89]Zr-DFO-VRC-HIVMAB060-00-AB, moves through the body in people with HIV-1 and healthy volunteers. This agent is a monoclonal antibody (a type of protein that can find and attach to specific targets) that is designed to target the HIV-1 virus. Researchers want to understand how much of this agent goes to different parts of the body and how long it stays there. This is not a treatment study, but rather an exploratory imaging study to learn more about how this agent behaves in the body. To join, you must be at least 18 years old. If you have HIV, your viral load (the amount of virus in your blood) must have been over 40 copies/mL in the last year, and your HIV-1 virus should be of a type that VRC01 can bind to. The study aims to measure the distribution of the imaging agent in the body over 120 hours.

Study design

This is an interventional study with a planned enrollment of 30 participants. It involves two phases, with the second phase depending on results from the first.

What's involved

You would receive one intravenous (IV) microdose of the imaging agent and then undergo up to four whole-body PET-MR (Positron Emission Tomography - Magnetic Resonance) scans over 72-120 hours.

Compensation

Not stated in the trial record.

Follow-up

Your body's exposure to the imaging agent will be measured for up to 120 hours after it is given.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.